August 27, 2018 / 6:06 AM / 3 months ago

Novo Nordisk's Ozempic consistently reduces risk of major cardiovascular events

COPENHAGEN, Aug 27 (Reuters) - Novo Nordisk says:

* Ozempic (semaglutide) consistently reduced the risk of major cardiovascular events across type 2 diabetes populations at high CV risk regardless of prior CV events at baseline

* Findings from two post-hoc subgroup analyses of the SUSTAIN 6 trial and one post-hoc meta-analysis of MACE in the SUSTAIN 1-5 trials were presented on Sunday at the ESC Congress 2018, organised by the European Society of Cardiology, in Munich, Germany.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below